MedPath

Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients

Phase 4
Completed
Conditions
Genital Herpes
Interventions
Drug: Placebo
Registration Number
NCT00477334
Lead Sponsor
Novartis
Brief Summary

This study will evaluate the safety and efficacy of single-day famciclovir episodic treatment in Black patients with recurrent genital herpes

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
463
Inclusion Criteria
  • Black men or women 18 years or older
  • History of recurrent genital herpes with at least 4 recurrences in preceding 12 months or in preceding 12 months prior to using suppressive antiviral therapy
  • Documented herpes simplex virus type 2 (HSV-2) seropositivity
  • Willingness to discontinue suppressive therapy during study, if applicable
  • Willingness and ability to comply with the study protocol
Exclusion Criteria
  • Pregnant or breastfeeding women
  • Women of childbearing potential not using accepted methods of contraception
  • Hypersensitivity to famciclovir or drugs with similar chemical structures
  • Renal dysfunction
  • Known or suspected to have decompensated liver disease
  • Known to have gastrointestinal malabsorption
  • Known to be immunocompromised
  • Known to be hypersensitive to ingredients in study medication
  • Other protocol-defined inclusion/exclusion criteria may apply

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1FamciclovirFamciclovir 1000 mg; twice a day for one day.
2PlaceboPlacebo; twice a day for one day.
Primary Outcome Measures
NameTimeMethod
Investigator Assessed Time to Healing of All Non-aborted Genital Herpes Lesions21 days

Time to healing of all non-aborted genital herpes lesions, defined as the time from the first dose of study medication to the investigator-assessed time of healing (i.e. loss of all crusts and re-epithelialization of lesions; erythema may be present).

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants With Aborted and Non-aborted Genital Herpes Lesions During the Treatment Period21 days
Investigator Assessed Time to Healing of All Non-aborted and Aborted Genital Herpes Lesions21 days

Kaplan-Meier estimation.

Time to Resolution of Symptoms Associated With Recurrent Genital Herpes72 hour after initiation of study medication up to 21 days

Median time to resolution of symptoms: all symptoms, pain, burning, itching, tingling and tenderness associated with recurrent genital herpes estimated using Kaplan-Meier method.

Number of Participants With a Second Recurrence of Genital Herpes in the Follow-up Period6 months

Number of participants with a second recurrence of genital herpes in the follow-up period.

Time to Second Recurrence of Genital Herpes6 months

Kaplan Meier estimated time in days to second recurrent from treatment initiation and from the date of healing of aborted lesions.

The Number of Participants With Clinically Notable Shifts From Normal at Baseline by Hematology Test and TreatmentBaseline, Day 2

The number of participants with clinically noted shifts in Hematology tests from normal at baseline are graded based on Division of Microbiology and Infectious Diseases (DMID) toxicity tables from Grade 1 toxicity (smallest change) to Grade 4 toxicity (largest change). Grade 3 and 4 toxicities are considered to be clinically meaningful.

The Number of Participants With Clinically Notable Shifts From Normal at Baseline by Chemistry Test and TreatmentBaseline, Day 2

The number of participants with clinically noted shifts in Clinical Chemistry tests from normal at baseline are graded based on Division of Microbiology and Infectious Diseases (DMID) toxicity tables from Grade 1 toxicity (smallest change) to Grade 4 toxicity (largest change). Grade 3 and 4 toxicities are considered to be clinically meaningful.

SGPT(ALT)= Serum Glutamic Pyruvate Transaminase (Alanine Aminotransferase) and SGOT(AST)= Serum Glutamic Oxalacetic Transaminase (Aspartate Aminotransferase)

Trial Locations

Locations (43)

Perimeter Institute for Clinical Research Inc. ("PICR")

🇺🇸

Atlanta, Georgia, United States

Magee-Womens Hospital of UPMC

🇺🇸

Pittsburgh, Pennsylvania, United States

The Conant Foundation Quest Diagnostics

🇺🇸

San Francisco, California, United States

International Research Associates, LLC

🇺🇸

Miami, Florida, United States

Nevada Alliance Against Diabetes

🇺🇸

Las Vegas, Nevada, United States

R/D Clinical Research, Inc

🇺🇸

Houston, Texas, United States

Sun Research Institute

🇺🇸

San Antonio, Texas, United States

Medical Research Centers of South Florida, Inc.

🇺🇸

Hollywood, Florida, United States

Medical College of Georgia Hospital and Clinics

🇺🇸

Augusta, Georgia, United States

Metrolina Internal Medicine Internal Medicine Research

🇺🇸

Charlotte, North Carolina, United States

Medunsa Clinical Research Unit (MeCRU)

🇿🇦

Medunsa, South Africa

Providence Clinical Research

🇺🇸

Burbank, California, United States

Dermatology Research Associates

🇺🇸

Los Angeles, California, United States

AppleMed Research Inc.

🇺🇸

Miami, Florida, United States

Alia Clinical Research, INC

🇺🇸

Huntington Park, California, United States

Global Clinical Trials

🇿🇦

Port Elizabeth, South Africa

Soapstone Center for Clinical Research

🇺🇸

Decatur, Georgia, United States

Omni Fertility and Laser Institute

🇺🇸

Shreveport, Louisiana, United States

Private Practice

🇺🇸

Fort Worth, Texas, United States

Drs. AE and QE Bhorat

🇿🇦

Soweto, South Africa

The Clinical Trial Center, LLC

🇺🇸

Jenkintown, Pennsylvania, United States

Bertoni Mercy Clinic

🇿🇦

Mmakau Village GA Rankuwa, South Africa

Setshaba Research Centre

🇿🇦

Shoshanguve, South Africa

Umkomaas Clinical Research Site

🇿🇦

Umkomaas, South Africa

Women's Care Center, PLC: Research Memphis Associates

🇺🇸

Memphis, Tennessee, United States

Josha Research

🇿🇦

Bloemfontein, South Africa

Prime Cure Medicentre

🇿🇦

Durban, South Africa

Mount Vernon Clinical Research, LLC

🇺🇸

Sandy Springs, Georgia, United States

Planned Parenthood of Arkansas and Eastern Oklahoma

🇺🇸

Tulsa, Oklahoma, United States

Peters Medical Research

🇺🇸

High Point, North Carolina, United States

Eastmed Clinical Trial Centre/Eastmed Medical Centre

🇿🇦

Pretoria, South Africa

Clinical Trials Management LLC

🇺🇸

Covington, Louisiana, United States

Drs. Essack and Mitha

🇿🇦

Johannesburg, South Africa

First Coast Primary Care Minority Physicians Research Alliance

🇺🇸

Jacksonville, Florida, United States

Segal Institute for Clinical Research Heathcare Clinical Data, Inc

🇺🇸

North Miami, Florida, United States

Tulane University Health Sciences Center

🇺🇸

New Orleans, Louisiana, United States

Dr. Mohammed

🇺🇸

St. Louis, Missouri, United States

UNC Clinical Research

🇺🇸

Raleigh, North Carolina, United States

Miray Medical Center

🇺🇸

Brockton, Massachusetts, United States

Pearl Medical Group, PLLC

🇺🇸

Southfield, Michigan, United States

International Research Center

🇺🇸

Towson, Maryland, United States

Millennium Clinical Trials, LLC

🇺🇸

Arlington, Virginia, United States

Hawthorne Medical Research, Inc.

🇺🇸

Winston-Salem, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath